Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'

Nils Landegren, Lindsey B. Rosen, Eva Freyhult, Daniel Eriksson, Tove Fall, Gustav Smith, Elise M.N. Ferre, Petter Brodin, Donald Sharon, Michael Snyder, Michail Lionakis, Mark Anderson, Olle Kämpe

Research output: Contribution to journalArticlepeer-review

6 Citations (SciVal)

Abstract

The AIRE gene plays a key role in the development of central immune tolerance by promoting thymic presentation of tissue-specific molecules. Patients with AIRE-deficiency develop multiple autoimmune manifestations and display autoantibodies against the affected tissues. In 2016 it was reported that: i) the spectrum of autoantibodies in patients with AIRE-deficiency is much broader than previously appreciated; ii) neutralizing autoantibodies to type I interferons (IFNs) could provide protection against type 1 diabetes in these patients (Meyer et al., 2016). We attempted to replicate these new findings using a similar experimental approach in an independent patient cohort, and found no evidence for either conclusion.

Original languageEnglish
Article numbere43578
JournaleLife
Volume8
DOIs
Publication statusPublished - 2019 Jun 27

Subject classification (UKÄ)

  • Endocrinology and Diabetes
  • Immunology in the medical area

Keywords

  • APS1/APECED
  • autoantibody
  • autoantigen
  • human
  • human biology
  • immune tolerance
  • immunology
  • inflammation
  • medicine
  • type 1 diabetes

Fingerprint

Dive into the research topics of 'Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies''. Together they form a unique fingerprint.

Cite this